Bristol-Myers Squibb Company ((BMY)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Bristol-Myers Squibb Company recently updated its clinical study on the effectiveness and safety of Deucravacitinib for treating non-pustular palmoplantar and genital psoriasis. Officially titled ‘A Phase 4, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Deucravacitinib in Participants With Non-Pustular Palmoplantar and Genital Psoriasis,’ the study aimed to provide critical insights into the treatment’s potential benefits and safety profile.
The study tested Deucravacitinib, an experimental drug, against a placebo to determine its efficacy in treating specific types of psoriasis. Deucravacitinib is designed to target and alleviate symptoms associated with these skin conditions.
This Phase 4 study was interventional, with participants randomly assigned to receive either the drug or a placebo. The study was double-blind, meaning neither the participants nor the investigators knew who received the actual drug, ensuring unbiased results. The primary goal was to assess treatment effectiveness.
The study commenced on October 9, 2023, but was terminated before completion. The last update was submitted on July 14, 2025. These dates are crucial for tracking the study’s progress and understanding its timeline.
The termination of this study could impact Bristol-Myers Squibb’s stock performance and investor sentiment, as it may raise concerns about the drug’s viability. Competitors in the dermatological treatment space may see this as an opportunity to advance their own products.
The study remains ongoing with updates available on the ClinicalTrials portal.